comparemela.com

Latest Breaking News On - Prnewswire curis inc - Page 4 : comparemela.com

Curis Announces $15 1 Million Registered Direct Offering

/PRNewswire/ Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK).

United statesNew yorkDrug administrationRoche groupExchange commissionCantor fitzgerald coPrnewswire curis incTruist securities incProspectus departmentTruist securitiesUnited states securitiesPost effective amendmentCantor fitzgeraldCapital marketsAim lymphomaAim leukemia

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

Jonathanb zungCompany fourthRoche groupDrug administrationCuris incPrnewswire curis incChief development officerInducement grantFourth amendedIncentive planAim lymphomaAim leukemiaOrphan drug designationTakeaim leukemiaHealth care amp hospitalsMedical pharmaceuticals

Curis Provides First Quarter 2023 Business Update

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesEvelo biosciencesJonathan zungJames dentzerExchange commissionCuris incDrug administrationEmory universityDevelopment officerRoche groupCuris executive teamBristol myers squibbPrnewswire curis incChief developmentRecent operationalChief development officer

Curis Provides Fourth Quarter 2022 Business Update

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesRoche erivedgeJames dentzerDrug administrationCuris incExchange commissionPrnewswire curis incRoche groupCompany takeaim leukemiaTakeaim leukemiaRecommended phaseChief executive officerRecent operationalComplete remissionPartial hematologicObjective response

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer,.

United statesPrnewswire curis inc

vimarsana © 2020. All Rights Reserved.